Biond Biologics
Tel Aviv, Israel· Est.
Innovative Israeli biotech delivering breakthrough immunotherapies and intracellular biologic delivery for cancer and autoimmune disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative Israeli biotech delivering breakthrough immunotherapies and intracellular biologic delivery for cancer and autoimmune disease.
OncologyImmunology
Technology Platform
INspire intracellular delivery platform for biologics and proprietary shedding‑blocker technology that stabilizes target proteins to restore immune function.
Opportunities
Advancing first‑in‑class shedding‑blockers and intracellular biologics could open new therapeutic classes and attract large pharma partnerships.
Risk Factors
Early‑stage clinical outcomes, manufacturing complexity, and competition from established immuno‑oncology companies pose significant risks.
Competitive Landscape
Biond differentiates through its intracellular delivery and shedding‑blocker platforms, competing with checkpoint inhibitor and CAR‑T developers but offering distinct mechanisms of action.